Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors

Boston Scientific (BSX) gained 1.11% on October 8, 2026, outperforming the broader market decline. The medical device manufacturer is expected to report Q3 earnings on October 28 with forecasted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY). However, the stock has declined 7.52% over the past month and holds a Zacks Rank of #4 (Sell) following a 1.3% decrease in consensus EPS estimates over the last 30 days. The stock trades at a Forward P/E of 12.78, below its industry average of 19.24.